BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of “Hold” from Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have earned a consensus recommendation of “Hold” from the four research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $35.50.

Several research analysts have commented on BTAI shares. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. HC Wainwright cut their price target on BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a report on Thursday. Finally, Zacks Research cut BioXcel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 28th.

Institutional Investors Weigh In On BioXcel Therapeutics

Several institutional investors have recently made changes to their positions in BTAI. Diversify Wealth Management LLC bought a new stake in shares of BioXcel Therapeutics during the 2nd quarter worth approximately $27,000. HRT Financial LP purchased a new stake in BioXcel Therapeutics in the fourth quarter worth $28,000. XTX Topco Ltd bought a new stake in shares of BioXcel Therapeutics during the second quarter worth $42,000. Goldman Sachs Group Inc. purchased a new stake in shares of BioXcel Therapeutics during the first quarter valued at $50,000. Finally, Geode Capital Management LLC grew its holdings in shares of BioXcel Therapeutics by 27.7% in the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares during the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Price Performance

Shares of NASDAQ BTAI opened at $1.61 on Friday. The stock has a market cap of $35.21 million, a PE ratio of -0.17 and a beta of 0.18. BioXcel Therapeutics has a 1 year low of $1.17 and a 1 year high of $8.08. The firm has a fifty day moving average price of $1.70 and a 200-day moving average price of $2.31.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.